Compare FNWB & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | BDSX |
|---|---|---|
| Founded | 1923 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 88.3M |
| IPO Year | 2015 | 2020 |
| Metric | FNWB | BDSX |
|---|---|---|
| Price | $10.24 | $11.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $13.50 | ★ $32.50 |
| AVG Volume (30 Days) | 29.7K | ★ 276.7K |
| Earning Date | 01-29-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $60,564,000.00 | ★ $80,173,000.00 |
| Revenue This Year | $22.61 | $22.01 |
| Revenue Next Year | $8.38 | $26.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 18.99 | ★ 22.29 |
| 52 Week Low | $6.05 | $3.44 |
| 52 Week High | $12.10 | $20.40 |
| Indicator | FNWB | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 57.37 |
| Support Level | $10.10 | $9.83 |
| Resistance Level | $10.58 | $11.00 |
| Average True Range (ATR) | 0.29 | 1.13 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 17.24 | 69.05 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.